upgrad neutral marin sink
upgrad neutral competitor data disappoint jnj/bayer
present disappoint data xarelto acut medic ill popul
esc data avoid worst case scenario bevyxxa
essenti remov potenti strong competitor put
pressur portola success chang medic practic
without help larger player still await better
commerci execut portola team comfort move
neutral rate target price potenti longer term
upsid bevyxxa importantli andexxa achiev level
commerci success previous believ possibl
like higher hurdl portola build market
disappoint marin data mean bevyxxa unlik see
competit post-hospit discharg market forese futur
howev without presenc portola work build
market believ adopt like slower
previous assum bevyxxa peak sale assum
slower market penetr bevyxxa market share
peak sale
dcf-deriv target price incorpor updat bevyxxa sale
estim expens adjust inclus termin valu base
reassess longev andexxa drive dcf
blue sky scenario two product gener combin
sale suggest valuat grey sky scenario
combin peak sale suggest valuat make
chang ep ep estim
main risk view
rapid/slow uptak bevyxxa andexxa expect plta
seen potenti takeout target
valuat metric
number share
rate under-perform neutral
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
portola biopharmaceut compani focus
develop commerci novel therapeut
area thrombosi hematolog disord inflamm
patient current limit approv treatment
price aug rate under-perform neutral target price analyst vamil
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base dcf analysi driven
combin global sale bevyxxa andexxa exceed
peak
grey sky valuat base dcf analysi driven
combin sale bevyxxa andexxa peak
 close
impact stock view
announc strong ceo could swing sentiment name continu
await appoint new ceo take leadership portola follow
departur former ceo li june given numer challeng portola
face develop commerci lead asset hire
respect ceo strong commerci experi could help improv investor
confid stori sentiment stock
on-tim gener andexxa prior approv supplement pa submiss
approv critic compani submit pa andexxa end
month imper pa get approv earli allow
broader uptak product given limit sale cash bevyxxa gener
believ investor expect full andexxa launch
delay would like repres risk downsid
impress cerdulatinib data portola present back june
current model risk-adjust peak sale product news around
acceler path market potenti partner asset could lead upsid
asset marin risk way think portola may attract attent
potenti take target includ potenti compani
xarelto lack potenti acut medic ill popul compani cover
believ could interest portola includ merck bristol believ
andexxa bevyxxa could perform better compani market
collabor licens revenu
good sold
incom loss oper
interest incom net
incom loss incom tax
provis incom tax
net incom attribut non-controlling interest
net incom loss attribut portola
compani mention price
